



Health
Canada Santé
Canada

Your health and
safety.. our priority.

Votre santé et votre
sécurité... notre priorité.

Re-evaluation Note

REV2025-01

Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2025-2030

(publié aussi en français)

15 July 2025

This document is published by the Health Canada Pest Management Regulatory Agency.
For further information, please contact:

Publications
Pest Management Regulatory Agency
Health Canada
2 Constellation Drive
8th floor, A.L. 2608 A
Ottawa, Ontario K1A 0K9

Internet: canada.ca/pesticides
pmra.publications-arla@hc-sc.gc.ca

Information Service:
1-800-267-6315
pmra.info-arla@hc-sc.gc.ca

Canada 

ISSN: 1925-0630 (print)
1925-0649 (online)

Catalogue number: H113-5/2025-1E (print version)
H113-5/2025-1E-PDF (PDF version)

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2025

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.

Table of Contents

Background.....	1
Work plan development.....	2
Part A Special reviews	3
Part A, Table 1 Publication target dates for proposed and final special review decisions.....	3
Part B Re-evaluations and standalone quantitative cumulative health risk assessment	8
Part B, Table 1 Publication target dates for proposed and final re-evaluation decisions, and cumulative health risk assessment project plans	8
Part C Re-evaluations – Early stage of re-evaluation process	11
Part C, Table 1 List of actives (in alphabetical order) for which the scoping reviews are targeted first.....	11
Part C, Table 2 List of actives (in alphabetical order) in the early part of the re-evaluation process	12
Part D Re-evaluation initiations between 1 April 2025 and 31 March 2030.....	16
Part D, Table 1 Re-evaluation initiations between 1 April 2025 and 31 March 2027 (based on initiation date).....	16
Part D, Table 2 Future re-evaluation initiations between 1 April 2027 and 31 March 2030	18

Background

The purpose of this document is to inform registrants, pesticide regulatory officials and the Canadian public of the re-evaluation and special review work (in other words, the post-market reviews) planned by Health Canada's Pest Management Regulatory Agency (PMRA) for the next five fiscal years from 1 April 2025 to 31 March 2030. This document presents updates to the information last published in Re-evaluation Note REV2024-01, *Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2024-2029*.

Health Canada regulates pesticides in Canada, with the primary objective of protecting the health of Canadians and the environment. A pesticide product may only be sold or used in Canada if it has been registered or otherwise authorized under the authority of the *Pest Control Products Act*. Health Canada uses a rigorous science-based risk assessment approach to ensure that the product meets health and environmental protection standards and has value.

As part of the post-market program, registered pesticides are re-evaluated on a cyclical basis to determine their continued acceptability. Pesticides may also be re-evaluated as a result of changes in the information required or the procedures used by Health Canada to determine that the pesticide meets current health, environment and value standards. The re-evaluation process is described in Regulatory Directive DIR2016-04, *Management of Pesticides Re-evaluation Policy*. In addition, a special review may be initiated at any time to address the identified aspect(s) of concern, and a special review is triggered only under certain circumstances. Special reviews differ from re-evaluations in that a special review is intended to examine only specific aspects of a pesticide. Additional information on special reviews can be found in the PMRA Guidance Document, *Approach to Special Reviews of Pesticides*.

As required under the *Pest Control Products Act*, Health Canada publishes all post-market proposed decisions for public consultation. Following consultation, comments and information submitted by the public and other stakeholders are considered before Health Canada issues a final decision. Stakeholders are encouraged to stay informed of upcoming consultations and decisions for pesticides by visiting the Pesticides and pest management section of Canada.ca.

This work plan includes the target dates for the proposed and final decisions to be published from 1 April 2025 and the status of all open re-evaluations and special reviews. In addition, new re-evaluations expected to be initiated from 1 April 2025 to 31 March 2030 are included for improved transparency for registrants and stakeholders.

This five-year work plan may change in response to workload and emerging issues that require priority action. During the course of the year, interested stakeholders can monitor the PMRA's Public Registry to view the announcement of new re-evaluations and special reviews, as well as other documents relevant to specific post-market reviews.

Work plan development

The re-evaluation and special reviews of several actives included in last year's plan (REV2024-01) have been carried over to this fiscal year due to the complex nature of the re-evaluations and the need to review large volumes of data and extensive use patterns. Resources were also focused on other priorities including an increased number of pre-market notices of objection and special review initiations. The number of re-evaluation initiations required as per the 15-year legislative requirement continues to be high and, given the current resource capacity considerations, the backlog is growing.

The PMRA's Continuous Oversight Model and Proportional Effort Framework will support operations and render them more efficient to ensure that the PMRA responds to emerging risks in a more timely manner and that the limited scientific resources are focused on issues that matter most. The PMRA consulted on the Proposed Continuous Oversight Policy in 2024. Over the course of the year, the PMRA plans to publish the policy on Continuous Oversight and begin implementing it. Future implementation of the proportional effort policy following consultation will enable the PMRA to better focus review efforts to increase overall protection and make progress to eliminate the re-evaluation backlog. Finally, Health Canada will seek independent scientific advice on post-market reviews through the Science Advisory Committee, when necessary, to better inform its evidence-based decisions.

The following Tables outline the target publication dates for the proposed and final decisions of special reviews and re-evaluations established based on the currently available resources. In addition, next milestone target dates for the three standalone quantitative cumulative health risk assessments initiated are also included.

Part A Special reviews

Special reviews are very focused and examine only specific aspects of a pesticide as outlined in PMRA Guidance Document, *Approach to Special Reviews of Pesticides*. While the aspect of concerns for each special review is included in the special review announcement available in the Public Registry, they are captured in the table below for easy access.

Part A, Table 1 Publication target dates for proposed and final special review decisions

Active ingredient name	Aspect of concerns	Target date ¹
Proposed special review decision (PSRD) – For consultation		
1 April 2025 to 31 March 2026		
Dicamba - Dicamba (present as acid, ester, salts) - Dicamba (present as n,n-bis(3-aminopropyl)methylamine salt) - Dicamba (present as monoethanolamine salt) - Dicamba (present as n-(2-aminoethyl)-1,2-ethanediamine salt) - Dicamba (present as acid) - Dicamba (present as potassium salt) - Dicamba (present as sodium salt) - Dicamba (present as dimethylamine salt) - Dicamba (present as diglycolamine salt) - Dicamba (present as isopropylamine salt) - Dicamba (present as diethanolamine salt)	Environment Risk to non-target terrestrial plants from the use of dicamba products (Over-the-Top (OTT) and non-OTT uses).	September 2025
Novaluron	Human health Potential dietary risks (food and water) from exposure to novaluron	October 2025
1 April 2026 to 31 March 2027		
Hydantoins - Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related hydantoins - Available bromine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related	Human health Potential occupational inhalation risk for workers handling halohydantoin products formulated as granules. Potential residential	Q1 (2026-27)

Active ingredient name	Aspect of concerns	Target date ¹
hydantoin - Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin, 1,3-dichloro-5,5-dimethylhydantoin, 1,3-dichloro-5-ethyl-5-methylhydantoin and related hydantoin - Available Chlorine Present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin	postapplication cancer risk from incidental oral exposure to bromate in outdoor swimming pools treated with bromine-based halohydantoin and in swimming pools, spas and hot tubs in combination with electrolysis, ozonation or UV devices.	
MCPA - MCPA (present as acid) - MCPA (present as amine salts: diethanolamine, dimethylamine, or mixed amines) - MCPA (present as esters) - MCPA (present as potassium salt or as sodium salt)	Human health Potential inhalation occupational (mixing/loading/applying) and residential risk from the use of MCPA.	Q1 (2026-27)
Ethalfluralin	Human health Potential cancer risks from occupational exposure to ethalfluralin for: <ul style="list-style-type: none"> • operators who are mixing and loading granular fertilizers with ethalfluralin products in commercial blending facilities; and • custom applicators (in field) of the liquid-fertilizer blends. 	Q2 (2026-27)
Propiconazole	Human health Potential exposure to propiconazole's transformation products (NOA436613, SYN547889, and CGA91305) in groundwater (drinking water). Environment Potential reproductive risk to fish	Q2 (2026-27)
Glufosinate ammonium	Human health	Q4 (2026-27)

Active ingredient name	Aspect of concerns	Target date ¹
	<p>Potential reproductive toxicity (including developmental toxicity);</p> <p>Potential occupational health risk; and</p> <p>Potential bystander risk.</p>	
1 April 2027 to 31 March 2028		
Ethofumesate	<p>Human health</p> <p>Potential risk from exposure to ethofumesate and transformation products NC 8493, NC 9607, and NC 20645 in drinking water; and</p> <p>Environment</p> <p>Potential risk to terrestrial and aquatic plants.</p>	Q1 (2027-28)
Thiacloprid	<p>Human health</p> <p>Potential exposure to thiacloprid's transformation products M30, M34, and M46 in groundwater (drinking water)</p>	Q2 (2027-28)
Chlorpropham	<p>Human health</p> <p>Dietary (food only) risk from exposure to chlorpropham and 3-chloroaniline residues.</p>	Q3 (2027-28)
Desmedipham	All products discontinued. Special review closed.	N/A
Final special review decision (SRD)		Target date¹
1 April 2025 to 31 March 2026		
Methyl bromide	<p>Human health</p> <p>Potential for risk from occupational exposure.</p> <p>Potential for risk to bystanders.</p>	June 2025
Chlorothalonil	<p>Human health</p> <ul style="list-style-type: none"> • Potential exposure to metabolites R417888, 	October 2025

Active ingredient name	Aspect of concerns	Target date ¹
	<p>R419492, R471811, SYN507900, M3, M11, M2, M7 and M10 from groundwater.</p> <ul style="list-style-type: none"> • Potential carcinogenicity of chlorothalonil (related to dietary exposure). • Potential genotoxicity of chlorothalonil metabolites. <p>Environment</p> <ul style="list-style-type: none"> • Potential changes to environmental fate and ecotoxicological endpoints (including parent and transformation products). • Potential risk to amphibians and fish. 	
Pydiflumetofen	<p>Human health</p> <p>Potential occupational inhalation risk</p>	December 2025
1 April 2026 to 31 March 2027		
Atrazine	<p>Human health and environment</p> <p>Potential changes to toxicology endpoint(s) used for previous human health and environmental risk assessments.</p> <ul style="list-style-type: none"> • The impact of those potential changes to human health from atrazine in drinking water. • The impact of those potential changes to the environment from atrazine in surface water. 	Q2 (2026-27)
1 April 2027 to 31 March 2028		
Iodocarb (3-iodo-2-propynyl butyl carbamate)	Human health	Q4 (2027-28)

Active ingredient name	Aspect of concerns	Target date ¹
	Potential dermal and inhalation risks of concern for secondary workers (machinists) exposed to iodocarb-treated metalworking fluids (MWF). Potential dermal and inhalation risks of concern for mixers/loaders treating MWF with iodocarb.	

¹ Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

Part B Re-evaluations and standalone quantitative cumulative health risk assessment

Based on the currently available resources, the PMRA has established target publication dates for the proposed and final decisions of the re-evaluations that are in the review stage, as well as the next milestone target dates for the three standalone quantitative cumulative health risk assessments.

Part B, Table 1 Publication target dates for proposed and final re-evaluation decisions, and cumulative health risk assessment project plans

Active ingredient name	Re-evaluation category	Target date ¹
Proposed re-evaluation decisions (PRVD) – For consultation		
1 April 2025 to 31 March 2026		
Potassium bicarbonate	2	June 2025
Sulphur	2	June 2025
Ferric Sodium Ethylenediaminetetraacetic Acid	3	September 2025
DEET plus related active toluamides	1	October 2025
Iodosulfuron-methyl-sodium	3	October 2025
Prohexadione calcium	3	December 2025
Famoxadone	1	January 2026
1 April 2026 to 31 March 2027		
Mecoprop cluster: - Mecoprop-P (present as Acid) - Mecoprop-P (present as Dimethylamine Salt) - Mecoprop-P (present as Potassium Salt)	1	Q1 2026-27
Fenamidone	1	Q2 (2026-27)
Nonylphenoxypolyethoxyethanol	3	Q2 (2026-27)
Clothianidin general re-evaluation	1	Q3 (2026-27)
Cyazofamid	3	Q3 (2026-27)
Cyprodinil	1	Q3 (2026-27)
Gibberellins cluster: - Gibberellic acid - Gibberellins A4A7	2	Q3 (2026-27)
Thiamethoxam general re-evaluation	1	Q3 (2026-27)
Glufosinate ammonium	1	Q4 (2026-27)
Spinetoram	1	Q4 (2026-27)
Spinosad	1	Q4 (2026-27)

Active ingredient name	Re-evaluation category	Target date ¹
Rodenticide Cluster: - Brodifacoum - Bromadiolone - Bromethalin - Chlorophacinone - Diphacinone (present in free form or as sodium salt) - Warfarin (present in free form or as sodium salt) - Zinc phosphide - Difethialone	1	Q4 (2026-27)
1 April 2027 to 31 March 2028		
Boscalid	2	Q1 (2027-28)
D-cis, trans-allethrin	1	Q1 (2027-28)
Ethofumesate	1	Q1 (2027-28)
(S)-Methoprene	2	Q1 (2027-28)
Acetamiprid	1	Q2 (2027-28)
Fluazinam	1	Q2 (2027-28)
Thiacloprid	1	Q2 (2027-28)
Methoxyfenozide	1	Q3 (2027-28)
Metribuzin	1	Q3 (2027-28)
Naled	1	Q3 (2027-28)
Phorate	1	Q3 (2027-28)
Picolinafen	1	Q3 (2027-28)
Prothioconazole	1	Q3 (2027-28)
6-Benzylaminopurine	1	Q4 (2027-28)
Bensulide	1	Q4 (2027-28)
Tetrachlorvinphos	1	Q4 (2027-28)
Cumulative risk assessment		
Cumulative Health Risk Assessment: N-Methyl Carbamates – Consultation for a proposed decision	1	Q1 (2027-28)
Cumulative Health Risk Assessment: Organophosphates – project plan ²	1	February 2026
Cumulative Health Risk Assessment: Triazole – project plan ²	1	Q1 (2026-27)
Final re-evaluation decision (RVD)		Target date¹
1 April 2025 to 31 March 2026		
Methyl bromide	1	June 2025
3-Methyl-2-Cyclohexen-1-one	3	June 2025
Abamectin	1	July 2025
<i>Streptomyces lydicus</i> Strain WYEC108	3	August 2025
German Cockroach Extract	3	September 2025

Active ingredient name	Re-evaluation category	Target date ¹
Fatty Acid cluster: - Potassium Salts of Fatty Acids - Triethanolamine Salts of Fatty Acids - Fatty Acids - Ammonium Salt of Fatty Acid	2	November 2025
Carbon dioxide cluster: - Carbon dioxide gas - Liquid carbon dioxide	2	November 2025
Cellulose	3	November 2025
Silicon dioxide cluster: - Silica aerogel - Silicon dioxide	3	January 2026
1 April 2027 to 31 March 2028		
S-metolachlor and R-enantiomer	1	Q2 (2027-28)
Azoxystrobin	1	Q4 (2027-28)

¹ Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

² A separate project plan will be published as per process described in Science Policy Note SPN2018-02, *Cumulative Health Risk Assessment Framework*.

Part C Re-evaluations – Early stage of re-evaluation process

The re-evaluations of the following active ingredients are in the early stage of the re-evaluation process. The PMRA will focus on the scoping reviews of these actives to determine the re-evaluation categories. Table 1 is the list of actives targeted first. The outcome of the scoping reviews will further inform prioritization of active ingredients for review phase, and the expected timelines for their public consultation will be included in the work plan to be published in spring 2026.

Part C, Table 1 List of actives (in alphabetical order) for which the scoping reviews are targeted first

Active ingredient name
10,10'-Oxybis(Phenoxarsine)
2-(Hydroxymethyl)-2-Nitro-1,3-Propanediol
2-Phenylphenol and Salts cluster: <ul style="list-style-type: none"> - 2-Phenylphenol - 2-Phenylphenol (present as Potassium Salt) - 2-Phenylphenol (present as Sodium Salt)
2-(Thiocyanomethylthio)Benzothiazole
Aminopyralid <ul style="list-style-type: none"> - Aminopyralid - Aminopyralid Triisopropanolamine Salt - Aminopyralid Potassium Salt
Ammonium Bromide
Antimicrobial cluster <ul style="list-style-type: none"> - 1,2-Benzisothiazolin-3-One - 2-Methyl-4-Isothiazolin-3-One - 4,5-Dichloro-2-N-Octyl-3(2H)-Isothiazolone - 5-Chloro-2-methyl-4-isothiazolin-3-One
<i>Bacillus thuringiensis ssp. Tenebrionis</i>
<i>Bacillus thuringiensis subspecies kurstaki (All Strains)</i>
<i>Bacillus thuringiensis, Serotype H-14</i>
<i>Beauveria bassiana Strain Hf23</i>
Bispyribac-Sodium
<i>Clonostachys rosea Strain J1446</i>
<i>Coniothyrium minitans Strain Con/M/91-08</i>
Cyprosulfamide
Fluvalinate-Tau
<i>Metarhizium brunneum Strain F52</i>
Methylene Bis(Thiocyanate)
Mineral Oil
N-Alkyl(25% C12, 60% C14, 15% C16)Dimethylbenzylammonium Chloride

Active ingredient name
N-Dialkyl(5% C12, 60% C14, 30% C16, 5% C18)Methylbenzylammonium Chloride
Ozone
Pyrimethanil
Pyroxsulam
Tetrakis(hydroxymethyl) Phosphonium Sulphate

Part C, Table 2 List of actives (in alphabetical order) in the early part of the re-evaluation process

Based on available resources, scoping reviews of actives in Table 2 will be targeted following the completion of the actives in Table 1 above, and Health Canada will provide an updated status of the following actives in the work plan to be published in spring 2026.

Active ingredient name
1,2-Dibromo-2,4-Dicyanobutane
2,4-D cluster: <ul style="list-style-type: none"> - 2,4-D (present as Acid) - 2,4-D (present as Amine Salts: Dimethylamine Salt, Diethanolamine Salt, or Other Amine Salts) - 2,4-D (present as choline salt) - 2,4-D (present as Low Volatile Esters)
Acequinocyl
Acifluorfen, present as Sodium Salt
Alkyl Dimethyl Benzyl Ammonium Chloride Cluster (ADBAC): <ul style="list-style-type: none"> - N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Chloride - N-Alkyl (68% C12, 32% C14) Dimethyl Ethylbenzyl Ammonium Chloride - N-Alkyl (5% C12, 60% C14, 30% C16, 5% C18) Dimethyl Benzyl Ammonium Chloride - N-Alkyl (67% C12, 25% C14, 7% C16, 1% C18) Dimethyl Benzyl Ammonium Chloride - Diisobutylphenoxyethoxyethyl Dimethyl Benzyl Ammonium Chloride - N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Saccharinate
Antimicrobials cluster: <ul style="list-style-type: none"> - 2,2-Dibromo-3-Nitrilopropionamide - Bronopol
Atrazine (plus related active Triazines)
Bentazon cluster: <ul style="list-style-type: none"> - Bentazon (present as Sodium Salt) - Bentazone
Bifenazate
Bromacil (present in free form, as Dimethylamine Salt, or as Lithium Salt)
Bromoxynil
Carbendazim
Carfentrazone-Ethyl
Chlorpropham
Chlorantraniliprole
Clomazone

Active ingredient name
Cloransulam-Methyl
Daminozide
Dicamba cluster: <ul style="list-style-type: none"> - Dicamba (present as Acid) - Dicamba (present as Acid, Ester, Salts) - Dicamba (present as Diethanolamine Salt) - Dicamba (present as Diglycoamine Salt) - Dicamba (present as Dimethylamine Salt) - Dicamba (present as Isopropylamine Salt) - Dicamba (present as Monoethanolamine Salt) - Dicamba (present as N-(2-Aminoethyl)-1,2-Ethanediamine Salt) - Dicamba (present as N,N-Bis(3-Aminopropyl)Methylamine Salt) - Dicamba (present as Potassium Salt) - Dicamba (present as Sodium Salt)
Dichlobenil
Didecyl Dimethyl Ammonium Chloride Cluster (DDAC): <ul style="list-style-type: none"> - Didecyl Dimethyl Ammonium Chloride – Other - Didecyldimethylammonium (present as Carbonate and Bicarbonate Salts) - Dioctyl Dimethyl Ammonium Chloride (present as Carbonate and Bicarbonate Salts) - Octyl Decyl Dimethyl Ammonium Chloride - Oxydiethylene Bis(Alkyl Dimethyl Ammonium Chloride)
Diiflubenzuron
Diphenylamine
Diuron
Dioxaborinanes cluster: <ul style="list-style-type: none"> - 2,2-(1-Methyltrimethylenedioxy)Bis-(4-Methyl-1,3,2-Dioxaborinane) - 2,2-Oxybis(4,4,6-Trimethyl-1,3,2-Dioxaborinane)
Dodine
Endothal cluster: <ul style="list-style-type: none"> - Endothal - Endothal, present as N,N-Dimethylalkylamine Salt
EPTC (S-ethyl N,N-dipropylcarbamoate)
Etridiazole
Fenbutatin Oxide
Fish toxicants cluster: <ul style="list-style-type: none"> - 4-Nitro-3-(trifluoromethyl) phenol sodium salt - Niclosamide
Flumioxazin
Glutaraldehyde
Imazapyr
Ipconazole
Maleic Hydrazide
Mandipropamid

Active ingredient name
MCPA cluster: <ul style="list-style-type: none"> - MCPA (present as Acid) - MCPA (present as Amine Salts: Diethanolamine, Dimethylamine, or Mixed Amines) - MCPA (present as Esters) - MCPA (present as Potassium Salt or as Sodium Salt)
Mesotrione
Metalaxyl cluster: <ul style="list-style-type: none"> - Metalaxyl - Metalaxyl-M and S-Isomer
Metaldehyde
Naphthalene Acetic Acid (present as Ethyl Ester, Sodium Salt, or as Ammonium Salt)
Napropamide
Novaluron
Oxamyl
Oxirane Derivatives - 50% Minimum
Oxyfluorfen
Pendimethalin
Phosphonic acid cluster: <ul style="list-style-type: none"> - Mono- and Di-Potassium Salt of Phosphorous Acid - Mono- and Di-basic Sodium, Potassium, and Ammonium Phosphites
Picloram cluster: <ul style="list-style-type: none"> - Picloram (present as Potassium Salt) - Picloram (present as Acid) - Picloram (present as Amine Salts)
Pinoxaden
Prometryne Plus Related Active Triazines
Pyraclostrobin
Pyrasulfotole
Rotenone
Sodium Chlorite and Sodium Chlorate cluster (industrial uses): <ul style="list-style-type: none"> - Sodium Chlorite - Sodium Chlorate
Spirodiclofen
Spiromesifen

Active ingredient name
Spirotetramat
Streptomycin
Sulfentrazone
Sulfonyl Ureas cluster: <ul style="list-style-type: none"> - Chlorsulfuron - Ethametsulfuron-Methyl - Metsulfuron-Methyl - Nicosulfuron - Rimsulfuron - Thifensulfuron-Methyl
Sulfuryl Fluoride
Terbacil
Thiencarbazone-Methyl
Topramezone
Triallate
Triazinetrione cluster: <ul style="list-style-type: none"> - Available Chlorine, present as Sodium Dichloro-S-Triazinetrione - Available Chlorine, present as Trichloro-S-Triazinetrione - Trichloro-S-Triazinetrione - Available Chlorine present as Trichloro-S-Triazinetrione and Sodium Dichloro-S-Triazinetrione
Triclopyr (present as Butoxyethyl Ester)
Trifloxystrobin

Note: The following actives included in the REV2024-01 were discontinued following the initiations, and therefore their re-evaluations were closed:

- Sethoxydim (The discontinued products are being phased out and the last date of permitted use is 9 October 2027)
- Propylene glycol
- Pyrazon

Part D Re-evaluation initiations between 1 April 2025 and 31 March 2030

Under the *Pest Control Products Act*, the PMRA is mandated to initiate re-evaluations for each registered pesticide on a 15-year cycle, based on the most recent major decision affecting the registration, including its initial registration (subsection 16(2) of the *Pest Control Products Act*). On a yearly basis, the PMRA updates the list of re-evaluations to be initiated in the next five fiscal years.

Part D, Table 1 Re-evaluation initiations between 1 April 2025 and 31 March 2027 (based on initiation date)

To further improve transparency for stakeholders and registrants, specific month of initiation of re-evaluation is included.

Active ingredient name	Initiation dates
1 April 2025 – 31 March 2026	
Dimethenamid-P	April 2025
Formetanate Hydrochloride	April 2025
Hexazinone	April 2025
<i>Nosema (Paranosema) locustae</i> Canning	April 2025
Lime Sulphur Or Calcium Polysulphide	May 2025
<i>Beauveria bassiana</i> Strain GHA	June 2025
Carbathiin	June 2025
Tribenuron-Methyl	June 2025
Dithiopyr	September 2025
N-Decanol	September 2025
N-Octanol	
Phenmedipham	September 2025
Propyzamide	September 2025
Trifluralin	September 2025
<i>Verticillium albo-atrum</i> , Isolate Wcs850	October 2025
Alkyl trimethylenediamines cluster: <ul style="list-style-type: none"> - N-Coco-Alkyltrimethylene Diamines present as Monobenzoate Salt - Alkyl-1,3-Propylene Diamine Acetates - 1-Alkylamino-3-Aminopropane (Alkyl Groups As Derived From Coconut Oil Fatty Acids) 	December 2025
Saflufenacil	February 2026
Chlormequat Chloride	March 2026
Simazine Plus Related Active Triazines	March 2026

Active ingredient name	Initiation dates
1 April 2026 – 31 March 2027	
Diquat	April 2026
Iron (present as FeHEDTA)	April 2026
Tembotrione	April 2026
Animal repellent cluster: <ul style="list-style-type: none"> - Castor Oil - Dried Eggs - Fish Meal Mixture - Fish Oil Mixture - Meat Meal Mixture - Wintergreen Oil - Garlic Oil 	May 2026
Dichlorprop P-Isomer (Present as 2-Ethylhexyl Ester)	June 2026
Naphthlene	June 2026
<i>Pseudomonas syringae</i> – Strain Esc-10	July 2026
<i>Lactobacillus casei</i> Strain LPT-111 <i>Lactobacillus rhamnosus</i> Strain LPT-21 <i>Lactococcus lactis ssp. cremoris</i> Strain M11/CSL <i>Lactococcus lactis ssp. lactis</i> Strain L164/CSL <i>Lactococcus lactis ssp. lactis</i> Strain L1102/CSL Lactic Acid Citric Acid	July 2026
Mesosulfuron-Methyl	August 2026
Metrafenone	September 2026
Paradichlorobenzene	September 2026
Tefluthrin	September 2026
Thymol	October 2026
Imazethapyr	October 2026
Trimethoxysilyl quats cluster: <ul style="list-style-type: none"> - 3-(Trihydroxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trimethoxysilsyl quats) - 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trihydroxysilyl quats) 	October 2026
Diodofon	October 2026
Hexahydro-1,3,5-Tris(2-Hydroxyethyl)-S-Triazine	October 2026
Oxalic Acid Dihydrate	November 2026
D-Limonene	November 2026
Flonicamid	December 2026
Saponins Of Chenopodium Quinoa	December 2026
1,4-Dimethylnaphthalene	January 2027
Tralkoxydim	January 2027
Iodocarb – Other	March 2027
Thiabendazole	March 2027

Note: The following actives included in the REV2024-01 for initiation in the fiscal year of 2025-26 will not be initiated:

- Imazamethabenz-Methyl and R-(-)-1-Octen-3-ol will not be initiated as there are no associated registered end-use products.
- Oxycarboxin, diazinon, bifenthrin, desmedipham and *Pseudomonas fluorescens* A506 will not be initiated as these products were discontinued.

Note: The following active included in the REV2024-01, initiated in the fiscal year of 2025-26 was discontinued following the initiation, and therefore its re-evaluation was closed:

- *Nosema (Paranosema) locustae* Canning

Note: The following actives included in the REV2024-01 for initiation in the fiscal year 2026-27 will not be initiated:

- Dichlorprop-P and dichlorprop-P (present as dimethylamine salt) will not be initiated as there are no associated end-use products currently registered in Canada.
- Sodium fluoride, butoxypolypropylene glycol, and acibenzolar-S-methyl will not be initiated as all of associated products were discontinued.

Part D, Table 2 Future re-evaluation initiations between 1 April 2027 and 31 March 2030

The initiations for the active ingredients in the following table will be updated annually.

1 April 2027 to 31 March 2028
Heavy duty wood preservative cluster: <ul style="list-style-type: none"> - Arsenic Acid - Chromic Acid - Creosote - Zinc (present as Zinc Oxide) - Copper (present as Basic Copper Carbonate)
Hydantoin cluster: <ul style="list-style-type: none"> - Available Bromine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins - Available Chlorine present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin - Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins - Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5-Ethyl-5-Methylhydantoin and Related Hydantoins
<i>Bacillus firmus</i> I-1582
Clopyralid
Copper (present as Copper 8-Quinolinolate)
Copper (present as Copper Naphthenate)
Zinc as Elemental (present as Zinc Naphthenate)
<i>Cydia pomonella granulovirus</i> (Strain M)
Extract of <i>Reynoutria sachalinensis</i>
Fluopicolide
Formaldehyde
Paraformaldehyde
Icaridin

Indaziflam
Metofluthrin
Oriental Mustard Seed Meal
<i>Paecilomyces fumosoroseus</i> Strain FE 9901
Penflufen
Penthiopyrad
<i>Phoma macrostoma</i>
Propiconazole
<i>Trichoderma asperellum</i> Strain T34
1 April 2028 to 31 March 2029
Ametoctradin
Ammonia (present as Ammonium Sulfate)
<i>Aureobasidium pullulans</i> cluster:
- <i>Aureobasidium pullulans</i> Strain DSM 14940 and DSM 14941
- <i>Aureobasidium pullulans</i> Strain DSM 14940
- <i>Aureobasidium pullulans</i> Strain DSM 14941
<i>Bacillus subtilis</i> var. <i>amyloliquefaciens</i> Strain FZB24
<i>Clavibacter michiganensis</i> spp. <i>michiganensis</i> Bacteriophage
Cloquintocet-Mexyl
Denatonium Benzoate
Ethalfluralin
Fenoxaprop-P-Ethyl
Fluazifop-P-Butyl and S-Isomer
Fluopyram
Fluoxastrobin
Fluxapyroxad
Kasugamycin (Present as Hydrochloride Hydrate)
Malathion
MCPB (Present as Sodium Salt)
Mint oil cluster:
- Cornmint Oil
- Methyl Salicylate
Octadecadien-1-ol cluster:
- (E,Z)-2,13-Octadecadien-1-yl Acetate
- (Z,Z)-3,13-Octadecadien-1-ol
- (E,Z)-3,13-Octadecadien-1-ol
Picoxystrobin
Poly[Oxyethylene(Dimethyliminio)Ethylene (Dimethyliminio)Ethylene Dichloride]
Potassium Dimethyldithiocarbamate Salts
<i>Pseudomonas fluorescens</i> Strain CL145A
Pyroxasulfone
Sedaxane
Sulfoxaflor
Tetraconazole
<i>Trichoderma virens</i> Strain G-41

1 April 2029 to 31 March 2030
3-Decen-2-One
<i>Bacillus subtilis</i> Strain GB03
Chlorfenapyr
Cyantraniliprole
Ethylene Oxide
Garlic Juice
Garlic Powder
Halosulfuron (Present as Methyl Ester)
Myclobutanil
P-Menthane-3,8-Diol And Related Oil Of Lemon Eucalyptus Compounds
<i>Streptomyces acidiscabies</i> Strain RI-110t Cells And Spent Fermentation Media
Tea Tree Oil
Tributyl Tetradecyl Phosphonium Chloride